NBY
AMEX · Pharmaceuticals
Novabay Pharmaceuticals Inc
$1.53
-0.12 (-7.27%)
Financial Highlights (FY 2026)
Revenue
97.74M
Net Income
-72,173,849
Gross Margin
66.3%
Profit Margin
-73.9%
Rev Growth
+5.1%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.3% | 66.3% | 57.3% | 57.3% |
| Operating Margin | -59.8% | -53.8% | 32.8% | 31.8% |
| Profit Margin | -73.9% | -70.2% | 22.7% | 21.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 97.74M | 92.98M | 19.57M | 22.58M |
| Gross Profit | 64.76M | 61.61M | 11.22M | 12.95M |
| Operating Income | -58,475,567 | -50,064,697 | 6.41M | 7.17M |
| Net Income | -72,173,849 | -61,792,678 | 4.44M | 4.92M |
| Gross Margin | 66.3% | 66.3% | 57.3% | 57.3% |
| Operating Margin | -59.8% | -53.8% | 32.8% | 31.8% |
| Profit Margin | -73.9% | -70.2% | 22.7% | 21.8% |
| Rev Growth | +5.1% | +5.1% | -0.9% | +13.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 6.63M | 6.63M | 20.34M | 18.54M |
| Total Equity | 19.33M | 19.33M | 41.21M | 43.15M |
| D/E Ratio | 0.34 | 0.34 | 0.49 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -71,464,632 | -64,584,665 | 7.02M | 9.17M |
| Free Cash Flow | — | — | 4.00M | 3.41M |